Eijiro Nakamura
Overview
Explore the profile of Eijiro Nakamura including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
102
Citations
1999
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ogura J, Yamanoi K, Ishida K, Nakamura E, Ito S, Aoyama N, et al.
Exp Mol Med
. 2024 Dec;
56(12):2659-2672.
PMID: 39617788
Fatty acids are known to have significant effects on the properties of cancer cells. Therefore, these compounds have been incorporated into therapeutic strategies. However, few studies have examined the effects...
2.
Fujita K, Matsushita Y, Toyoda S, Kojima T, Yamashita S, Taniguchi H, et al.
World J Urol
. 2024 Sep;
42(1):536.
PMID: 39325218
Purpose: Metastatic non-clear cell renal cell carcinoma (nccRCC) is a heterogeneous disease with a poor prognosis and is treated with immunotherapy (IO)-based combinations according to the clear cell renal cell...
3.
Uchihara M, Tanabe A, Kojima Y, Shimoi T, Maeshima A, Umamoto K, et al.
Cancers (Basel)
. 2024 Jun;
16(12).
PMID: 38927897
Metastatic pheochromocytomas and paragangliomas (PPGLs) are rare endocrine malignancies with limited effective treatment options. The association between the tumor microenvironment (TME) with somatostatin receptor 2 (SSTR2) and hypoxia-induced factor-2α (HIF-2α)...
4.
Kirisawa T, Okuno T, Hagimoto H, Matsuda A, Maejima A, Shinoda Y, et al.
Int J Urol
. 2024 May;
31(7):804-812.
PMID: 38693651
Objectives: To determine the outcomes for elderly patients with de novo metastatic germ cell tumors and the influence of patient age on adherence to standard chemotherapy. Methods: A total of...
5.
Yoshikawa K, Hagimoto H, Nakamura E
Nihon Yakurigaku Zasshi
. 2024 May;
159(3):160-164.
PMID: 38692880
The 2019 Nobel Prize in Physiology or Medicine was awarded to Dr. William G. Kaelin Jr, Dr. Peter J. Ratcliffe, and Dr. Gregg L. Semenza for their elucidation of new...
6.
Kirisawa T, Nakamura E, Okuno T, Hagimoto H, Matsuda A, Shinoda Y, et al.
Int Cancer Conf J
. 2024 Mar;
13(2):98-102.
PMID: 38524658
Intermittent docetaxel therapy (IDT) is rarely used nowadays as a treatment option for men with metastatic castration-resistant prostate cancer (mCRPC) because of the widespread availability of androgen receptor axis-targeted therapy,...
7.
Matsuoka T, Sugiyama A, Miyawaki Y, Hidaka Y, Okuno Y, Sakai H, et al.
Cancer Sci
. 2023 Nov;
115(1):283-297.
PMID: 37923364
Androgen-deprivation therapy is a standard treatment for advanced prostate cancer. However, most patients eventually acquire resistance and progress to castration-resistant prostate cancer (CRPC). In this study, we established new CRPC...
8.
Ogata T, Aizawa R, Nakamura K, Kobayashi T, Akamatsu S, Nakamura E, et al.
Anticancer Res
. 2023 Jul;
43(8):3589-3596.
PMID: 37500135
Background/aim: The aim of this study was to evaluate the benefit of adding long-term adjuvant hormonal therapy to high-dose intensity-modulated radiation therapy for locally advanced prostate cancer patients with multiple...
9.
Ito K, Yamamoto T, Hayashi Y, Sato S, Nakayama J, Urabe F, et al.
Mol Oncol
. 2023 Jul;
17(10):2147-2167.
PMID: 37408474
Clinically, the osteolytic phenotype is rare in prostate cancer (PCa), and the prognosis is generally worse than that of the osteoblastic phenotype. Osteoblastic prostate cancer (BPCa) is a major type...
10.
Takamori H, Maeshima A, Kato I, Baba M, Nakamura E, Matsui Y
IJU Case Rep
. 2023 May;
6(3):161-164.
PMID: 37144078
Introduction: Renal cell carcinoma with amplification is rare and reportedly aggressive. We herein report a case of renal cell carcinoma with translocation and amplification in which long-term control was achieved...